JPWO2019140271A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019140271A5 JPWO2019140271A5 JP2020538844A JP2020538844A JPWO2019140271A5 JP WO2019140271 A5 JPWO2019140271 A5 JP WO2019140271A5 JP 2020538844 A JP2020538844 A JP 2020538844A JP 2020538844 A JP2020538844 A JP 2020538844A JP WO2019140271 A5 JPWO2019140271 A5 JP WO2019140271A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- conjugate
- pharmaceutical according
- effective amount
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023186470A JP7703001B2 (ja) | 2018-01-12 | 2023-10-31 | 相乗的がん治療 |
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862617095P | 2018-01-12 | 2018-01-12 | |
| US62/617,095 | 2018-01-12 | ||
| US201862674483P | 2018-05-21 | 2018-05-21 | |
| US62/674,483 | 2018-05-21 | ||
| US201862700147P | 2018-07-18 | 2018-07-18 | |
| US62/700,147 | 2018-07-18 | ||
| US201862711423P | 2018-07-27 | 2018-07-27 | |
| US201862711421P | 2018-07-27 | 2018-07-27 | |
| US62/711,423 | 2018-07-27 | ||
| US62/711,421 | 2018-07-27 | ||
| US201862716788P | 2018-08-09 | 2018-08-09 | |
| US201862716796P | 2018-08-09 | 2018-08-09 | |
| US62/716,796 | 2018-08-09 | ||
| US62/716,788 | 2018-08-09 | ||
| PCT/US2019/013314 WO2019140271A2 (en) | 2018-01-12 | 2019-01-11 | Synergistic cancer treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023186470A Division JP7703001B2 (ja) | 2018-01-12 | 2023-10-31 | 相乗的がん治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021510702A JP2021510702A (ja) | 2021-04-30 |
| JPWO2019140271A5 true JPWO2019140271A5 (https=) | 2022-01-19 |
| JP2021510702A5 JP2021510702A5 (https=) | 2022-01-19 |
Family
ID=67218383
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020538819A Pending JP2021510701A (ja) | 2018-01-12 | 2019-01-11 | 併用投与の毒性を最小化するためのプロトコルおよび検証用のイメージング剤 |
| JP2020538844A Pending JP2021510702A (ja) | 2018-01-12 | 2019-01-11 | 相乗的がん治療 |
| JP2023186470A Active JP7703001B2 (ja) | 2018-01-12 | 2023-10-31 | 相乗的がん治療 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020538819A Pending JP2021510701A (ja) | 2018-01-12 | 2019-01-11 | 併用投与の毒性を最小化するためのプロトコルおよび検証用のイメージング剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023186470A Active JP7703001B2 (ja) | 2018-01-12 | 2023-10-31 | 相乗的がん治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US20200360545A1 (https=) |
| EP (2) | EP3737383A4 (https=) |
| JP (3) | JP2021510701A (https=) |
| KR (2) | KR20200109345A (https=) |
| CN (2) | CN111587126A (https=) |
| AU (2) | AU2019208024A1 (https=) |
| CA (2) | CA3087628A1 (https=) |
| MX (3) | MX2020007306A (https=) |
| RU (1) | RU2020126774A (https=) |
| WO (2) | WO2019140266A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202116356A (zh) | 2019-07-10 | 2021-05-01 | 美商斯布雷克薩三號公司 | 作為治療劑之微管靶向藥劑之肽結合物 |
| CN114341162B (zh) | 2019-07-10 | 2025-10-17 | 赛博克萨2公司 | 作为治疗剂的细胞毒素的肽缀合物 |
| CN114615978A (zh) * | 2019-08-28 | 2022-06-10 | 普罗林科斯有限责任公司 | Dna损伤响应的偶联抑制剂 |
| CN119213060A (zh) * | 2022-04-14 | 2024-12-27 | 国立研究开发法人量子科学技术研究开发机构 | 单一高分子颗粒、活性分子复合物、单一高分子颗粒的制造方法、肿瘤尺寸的计测方法、肿瘤内微细结构的计测方法、生物体组织的成像方法、药物递送体系、造影剂试剂盒 |
| WO2024030998A2 (en) * | 2022-08-04 | 2024-02-08 | Prolynx Llc | Methods of treating cancer with long-acting topoisomerase i inhibitor |
| WO2024031005A2 (en) * | 2022-08-04 | 2024-02-08 | Prolynx Llc | Treating cancer with long-acting topoisomerase i inhibitor |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998030575A1 (en) | 1997-01-08 | 1998-07-16 | Proligo Llc | Bioconjugation of macromolecules |
| US7850990B2 (en) | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| US20040176270A1 (en) | 2002-07-12 | 2004-09-09 | Biomarin Pharmaceutical Inc. | Use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates |
| EP1580216B1 (en) | 2002-10-31 | 2014-05-14 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight derivatives of camptothecins |
| US20040247624A1 (en) | 2003-06-05 | 2004-12-09 | Unger Evan Charles | Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility |
| ES2629696T3 (es) | 2003-09-17 | 2017-08-14 | Nektar Therapeutics | Profármacos poliméricos multibrazo |
| US7462627B2 (en) | 2006-02-09 | 2008-12-09 | Enzon Pharmaceuticals, Inc. | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
| MX2009002855A (es) | 2006-09-15 | 2009-03-30 | Enzon Pharmaceuticals Inc | Profarmacos polimericos dirigidos que contienen enlazadores multifuncionales. |
| WO2009141826A2 (en) * | 2008-05-22 | 2009-11-26 | Ramot At Tel Aviv University Ltd. | Novel conjugates of polymers having a therapeutically active agent and an angiogenesis targeting moiety attached thereto and uses thereof in the treatment of angiogenesis related diseases |
| WO2009158668A1 (en) | 2008-06-26 | 2009-12-30 | Prolynx Llc | Prodrugs and drug-macromolecule conjugates having controlled drug release rates |
| CA2738807A1 (en) | 2008-10-21 | 2010-04-29 | Enzon Pharmaceuticals, Inc. | Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin |
| JP2012509469A (ja) | 2008-11-18 | 2012-04-19 | バクスター・インターナショナル・インコーポレイテッド | ポリエチレングリコールサンプルの多分散度および／または分子量分布を決定する方法 |
| WO2010138719A1 (en) | 2009-05-28 | 2010-12-02 | Mersana Therapeutics, Inc. | Polyal drug conjugates comprising variable rate-releasing linkers |
| ME03396B (me) | 2009-11-18 | 2020-01-20 | Nektar Therapeutics | Oblici kisele soli konjugata polimer-lek |
| EP2566335B1 (en) | 2010-05-05 | 2016-06-29 | Prolynx Llc | Controlled release of active compounds from macromolecular conjugates |
| EP2566334B1 (en) | 2010-05-05 | 2018-04-18 | Prolynx, LLC | Controlled drug release from solid supports |
| US8703907B2 (en) | 2010-05-05 | 2014-04-22 | Prolynx Llc | Controlled drug release from dendrimers |
| TW201215412A (en) | 2010-08-30 | 2012-04-16 | Sun Pharma Advanced Res Co Ltd | Stable pharmaceutical composition |
| ES2621857T3 (es) * | 2010-11-16 | 2017-07-05 | Array Biopharma, Inc. | Combinación de inhibidores de la cinasa 1 de punto de control e inhibidores de la cinasa WEE1 |
| WO2012088282A1 (en) | 2010-12-21 | 2012-06-28 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds |
| WO2013049719A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| IN2014MN01819A (https=) * | 2012-03-05 | 2015-07-03 | Univ Ramot | |
| TWI486341B (zh) * | 2012-05-18 | 2015-06-01 | 高雄醫學大學 | 抑制ａｔｒ與ｆａｎｃｄ２激活之組成物與方法 |
| US9863949B2 (en) * | 2013-05-31 | 2018-01-09 | Nektar Therapeutics | Method for predicting and evaluating responsiveness to cancer treatment with DNA-damaging chemotherapeutic agents |
| DK3052101T3 (da) * | 2013-10-04 | 2019-12-16 | Prolynx Llc | Konjugater af sn-38 med langsom frigivelse |
| WO2015066053A2 (en) * | 2013-10-28 | 2015-05-07 | Synta Pharmaceuticals Corp. | Targeted therapeutics |
| WO2015118338A1 (en) * | 2014-02-07 | 2015-08-13 | Mission Therapeutics Limited | Methods for exploiting synthetic lethality and chemo-sensitisation in dna damage response (ddr) pathways |
| WO2015183876A1 (en) * | 2014-05-28 | 2015-12-03 | Memorial Sloan Kettering Cancer Center | Bimodal fluorophore-labeled liposomes and associated methods and systems |
| CA2957721C (en) * | 2014-08-13 | 2021-04-13 | The Johns Hopkins University | Selective dendrimer delivery to brain tumors |
| WO2016028636A1 (en) | 2014-08-16 | 2016-02-25 | Memorial Sloan Kettering Cancer Center | Helical polycarbodiimide polymers and associated imaging, diagnostic, and therapeutic methods |
| JP6378584B2 (ja) | 2014-08-29 | 2018-08-22 | キヤノン株式会社 | 通信システム、画像処理装置、画像処理装置の制御方法、及びプログラム |
| US10196412B2 (en) * | 2014-12-24 | 2019-02-05 | The Board Of Trustees Of The Leland Stanford Junior University | Probe for imaging PARP-1 activity |
| PL3560924T3 (pl) | 2015-04-02 | 2021-10-11 | Merck Patent Gmbh | Imidazolonylochinoliny i ich zastosowanie jako inhibitorów kinazy atm |
| CA2980462C (en) * | 2015-04-07 | 2023-08-01 | The Curators Of The University Of Missouri | Nanoparticle immunoconjugates |
| WO2016176462A1 (en) * | 2015-04-28 | 2016-11-03 | University Of Central Florida Foundation, Inc. | Methods and compositions for theranostic nanoparticles |
| EP3337467B1 (en) * | 2015-08-20 | 2020-12-09 | Ipsen Biopharm Ltd. | Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment |
| US10821195B2 (en) | 2015-09-10 | 2020-11-03 | Memorial Sloan Kettering Cancer Center | Compositions for therapeutics, targeted PET imaging and methods of their use |
| ES2941968T3 (es) | 2015-10-01 | 2023-05-29 | The Whitehead Institute For Biomedical Res | Marcaje de anticuerpos |
| US11154538B2 (en) | 2016-02-29 | 2021-10-26 | Synta Pharmaceuticals Corporation | Combination therapy for treatment of ovarian cancer |
| WO2017172678A1 (en) * | 2016-03-30 | 2017-10-05 | Merrimack Pharmaceuticals, Inc. | Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan |
| JP7379795B2 (ja) | 2016-04-27 | 2023-11-15 | イミューノメディクス、インコーポレイテッド | チェックポイント阻害薬に再発／耐性を示す腫瘍を治療するための抗Ｔｒｏｐ－２－ＳＮ－３８抗体薬物複合体の効果 |
| CN109069666B (zh) | 2016-04-29 | 2023-04-04 | 纪念斯隆凯特琳癌症中心 | 使靶向颗粒穿透、分布和响应于恶性脑肿瘤中的组合物和方法 |
| CN106084005B (zh) * | 2016-06-15 | 2020-02-14 | 广州军区广州总医院 | 靶向生长抑素受体的Al18F-NOTA-PEG6-TATE及其制备方法和应用 |
| CN107050471A (zh) | 2016-12-27 | 2017-08-18 | 中国药科大学 | 基于富勒烯的靶向且具有快速清除特征的显像纳米探针及其制备方法和应用 |
-
2019
- 2019-01-11 MX MX2020007306A patent/MX2020007306A/es unknown
- 2019-01-11 CA CA3087628A patent/CA3087628A1/en active Pending
- 2019-01-11 WO PCT/US2019/013306 patent/WO2019140266A1/en not_active Ceased
- 2019-01-11 JP JP2020538819A patent/JP2021510701A/ja active Pending
- 2019-01-11 AU AU2019208024A patent/AU2019208024A1/en not_active Abandoned
- 2019-01-11 RU RU2020126774A patent/RU2020126774A/ru unknown
- 2019-01-11 EP EP19738883.8A patent/EP3737383A4/en not_active Withdrawn
- 2019-01-11 JP JP2020538844A patent/JP2021510702A/ja active Pending
- 2019-01-11 US US16/961,633 patent/US20200360545A1/en not_active Abandoned
- 2019-01-11 EP EP19738881.2A patent/EP3737416A4/en not_active Withdrawn
- 2019-01-11 CA CA3087967A patent/CA3087967A1/en active Pending
- 2019-01-11 WO PCT/US2019/013314 patent/WO2019140271A2/en not_active Ceased
- 2019-01-11 MX MX2020007442A patent/MX2020007442A/es unknown
- 2019-01-11 KR KR1020207023338A patent/KR20200109345A/ko not_active Ceased
- 2019-01-11 CN CN201980008252.XA patent/CN111587126A/zh active Pending
- 2019-01-11 AU AU2019206623A patent/AU2019206623A1/en not_active Abandoned
- 2019-01-11 US US16/961,640 patent/US11730836B2/en active Active
- 2019-01-11 KR KR1020207023337A patent/KR20200110377A/ko not_active Ceased
- 2019-01-11 CN CN201980008227.1A patent/CN111587115A/zh active Pending
-
2020
- 2020-07-13 MX MX2023005786A patent/MX2023005786A/es unknown
-
2023
- 2023-03-07 US US18/118,650 patent/US20230321286A1/en not_active Abandoned
- 2023-07-11 US US18/220,742 patent/US20240082436A1/en not_active Abandoned
- 2023-10-31 JP JP2023186470A patent/JP7703001B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113797341B (zh) | Atr抑制剂和parp1抑制剂联用在制备治疗乙肝相关性肝癌的药物中的用途 | |
| Boulikas | Molecular mechanisms of cisplatin and its liposomally encapsulated form, Lipoplatin™. Lipoplatin™ as a chemotherapy and antiangiogenesis drug | |
| Begg et al. | Strategies to improve radiotherapy with targeted drugs | |
| Shabason et al. | Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic | |
| US20210077625A1 (en) | Ray tracing technique for wireless channel measurements | |
| JP2021510702A5 (https=) | ||
| JP7703001B2 (ja) | 相乗的がん治療 | |
| US20230190694A1 (en) | Compositions for and methods of precision cancer treatment | |
| Oza et al. | Homologous recombination repair deficiency as a therapeutic target in sarcoma | |
| JP7614714B2 (ja) | 神経芽細胞腫及びその他のがん治療のための治療ナノ粒子 | |
| CN108025013A (zh) | 用于治疗骨髓瘤的赛度替尼 | |
| Kanvinde et al. | Pharmacokinetics and efficacy of orally administered polymeric chloroquine as macromolecular drug in the treatment of inflammatory bowel disease | |
| Cutsem et al. | The role of chemotherapy in the current treatment of gastric cancer | |
| CN110573166A (zh) | 用于癌症治疗的吉西他滨衍生物 | |
| WO2024035425A1 (en) | Compositions for and methods of precision cancer treatment | |
| US20050282893A1 (en) | Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors | |
| JPWO2019140271A5 (https=) | ||
| Zhang et al. | Autophagy in doxorubicin resistance: basic concepts, therapeutic perspectives and clinical translation | |
| CN112601527B (zh) | 用于有效预防和治疗的选择性抗癌剂 | |
| US20220288404A1 (en) | Methods for applying tumor treating fields in combination with cancer treating therapeutics | |
| US20230099637A1 (en) | Palladium Hyaluronic Acid Particles and Methods of Managing Cancer or Angiogenic Conditions | |
| Eatock et al. | A dose-finding study of raltitrexed (tomudex) with cisplatin and epirubicin in advanced gastro-oesophageal adenocarcinoma | |
| CN116672345A (zh) | Parp抑制剂和细胞毒性剂的联合产品及其用途 | |
| EP4489752A1 (en) | Treatment of clear cell renal cell carcinoma | |
| EP1606302A2 (en) | Methods and compositions for using suramin, pentosan polysulfate, telomerase antisense, and telomerase inhibitors |